Form 4: Emergent BioSolutions SVP Vests PSUs at 25% Target

Emergent BioSolutions' SVP, Products Business, Paul Anthony Williams, vested performance stock units at a 25% payout factor, receiving 8,655 shares and disposing of 1,022 for taxes.

Summary

• Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions Inc. (EBS), acquired 8,655 shares of common stock on February 6, 2026, at a price of $10.92 per share.
• These shares are reported as resulting from the vesting of performance stock units (PSUs) granted under the company's Stock Incentive Plan.
• The filing's explanation for this acquisition states that the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of the target, resulting in an actual award of 2,884 shares of common stock. This award is less than the 11,539 shares previously reported as potential awards.
• Williams also disposed of 1,022 shares of common stock at $10.92 per share on the same date to cover tax obligations associated with the vesting and settlement of restricted stock units.
• Following these transactions, Williams beneficially owns 76,194 shares of common stock directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal regarding the company's financial performance during the 2023-2025 period, as evidenced by the significantly low PSU payout factor for an executive.

Positives

• The SVP, Products Business, Paul Anthony Williams, continues to hold a significant number of shares (76,194) in the company, indicating continued alignment with shareholder interests.

Negatives

• The performance stock units (PSUs) for the 2023-2025 period vested at a payout factor of only 25% of the target.
• The actual award of shares from these PSUs, stated as 2,884 shares in the filing's explanation, is significantly less than the 11,539 shares previously reported as potential awards, suggesting underperformance against the set financial targets (cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue).

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, focusing instead on past performance metrics for executive compensation.

Industry Context

StockSavvy.ai notes that executive compensation tied to performance metrics like revenue and EBITDA is a standard practice across industries, including biotechnology. The 25% payout factor suggests that Emergent BioSolutions may have faced challenges in meeting its internal financial targets during the 2023-2025 period, which could reflect broader industry headwinds or company-specific operational issues.

Comparison to Industry Standards

• A 25% payout factor for performance-based compensation is significantly below typical target achievement levels, which often range from 75% to 125% for companies meeting or exceeding expectations. For example, a company like Pfizer or Johnson & Johnson would typically see higher payout factors for their executives if they met their financial goals.
• The underperformance against internal targets, as indicated by the low PSU payout, suggests that Emergent BioSolutions' financial results for the 2023-2025 period may have lagged behind industry peers who successfully navigated similar market conditions.

Stakeholder Impact

• Shareholders: The low PSU payout factor suggests that the company's financial performance during 2023-2025 may have been weaker than anticipated, potentially impacting shareholder value.
• Employees: Executive compensation tied to underperformance could signal broader challenges within the company, potentially affecting employee morale or future incentive programs.

Key Dates

Recommendation

While the insider transaction itself is routine, the underlying reason for the transaction – a significantly underperforming PSU payout (25% of target) – suggests that Emergent BioSolutions did not meet its financial goals for the 2023-2025 period. This indicates potential operational or market challenges. However, without further financial details from a comprehensive report (e.g., 10-K or 10-Q), a definitive 'sell' recommendation is premature. A 'hold' is appropriate to await more detailed financial disclosures that would provide a clearer picture of the company's current health and future prospects, especially given the future date of the transaction (Feb 2026).

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Transaction, Stock Vesting, Performance Stock Units, Executive Compensation, Paul Anthony Williams, Share Ownership